Ligand Pharmaceuticals Inc. Raises Fourth Quarter And Full Year 2013 Financial Forecast

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) is revising upward its previous revenue and net income guidance for the fourth quarter and full year 2013 as a result of higher-than-expected sales of Captisol® material. Ligand now expects total revenues for the fourth quarter of 2013 to be between $14.0 million and $14.5 million, compared with previous guidance of between $11.0 million and $12.0 million.

Help employers find you! Check out all the jobs and post your resume.